Migration NZAX Market to NZX Main Board – Cleansing Notice

17 December 2018
Client Market Services
NZX Limited
Level 1, NZX Centre
11 Cable Street
Wellington 6011

TRUSCREEN LIMITED – MIGRATION FROM NZAX MARKET TO NZX MAIN BOARD- CLEANSING NOTICE
Truscreen Limited (NZAX:TRU) has announced its intention to migrate from the NZAX Market to the
NZX Main Board. This process involves:
• TRU delisting and ceasing to have its ordinary shares quoted on NZAX, in accordance with the
NZAX Listing Rules; and

• listing and having its ordinary shares quoted on the NZX Main Board, in accordance with NZX
Main Board/Debt Market Listing Rules (Rules) 5.1.1 and 5.2.1.

As part of the migration to the NZX Main Board, NZX has requested TRU to issue a Cleansing Notice to
the market. Accordingly, TRU advises that as at the date of this notice, TRU is in compliance with:
1. its financial reporting obligations in terms of the Companies Act, the Financial Markets
Conducts Act, and the NZAX Market Listing Rules;

2. the continuous disclosure obligations and all other alternative disclosure obligations under
the listing rules of the NZAX market that apply to TRU’s quoted ordinary shares on the NZAX
Market;

3. the continuous disclosure obligations under the listing rules of the NZX Main Board as if the
shares on issue in TRU were quoted on the NZX Main Board as at the date of this notice; and

4. there is no material information (within the meaning of section 59 of the FMC Act applied as
if the offer was a regulated offer) that is not generally available to the market and has not
been disclosed to the market under a continuous disclosure obligation or an alternative
disclosure obligation.

On behalf of
TruScreen Limited

Martin Dillon
Chief Executive Officer
ENDS

For more information visit www.TruScreen.com or contact:
Martin Dillon
TruScreen CEO
Email: martindillion@truscreen.com
Guy Robertson
TruScreen Chief Financial Officer
Email: guyrobertson@truscreen.com

About TruScreen:
Watch our video on TruScreen
http://truscreen.com/truscreen-the-company/truscreen-
ultra-video/
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each
patient to protect against cross-infection.
For more information, visit our website at www.truscreen.com